Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 4,151 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 4,151 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $45.14, for a total transaction of $187,376.14. Following the transaction, the insider now directly owns 166,134 shares of the company's stock, valued at $7,499,288.76. The trade was a 2.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Monday, April 14th, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.72, for a total value of $92,937.92.
• On Monday, March 31st, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.77, for a total value of $89,863.72.
• On Tuesday, February 18th, Soleil Boughton sold 4,152 shares of Hims & Hers Health stock. The shares were sold at an average price of $60.69, for a total value of $251,984.88.
• On Monday, February 3rd, Soleil Boughton sold 4,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.30, for a total transaction of $146,600.90.
• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total transaction of $1,619,174.70.

Hims & Hers Health Stock Down 8.6 %

Hims & Hers Health stock traded down $2.54 during mid-day trading on Wednesday, reaching $26.92. 20,684,975 shares of the company's stock were exchanged, compared to its average volume of 15,200,932. The business's fifty day simple moving average is $38.25 and its 200 day simple moving average is $30.52. Hims & Hers Health, Inc. has a one year low of $11.20 and a one year high of $72.98. The firm has a market capitalization of $5.98 billion, a PE ratio of 61.18 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Institutional Trading of Hims & Hers Health

A number of large investors have recently bought and sold shares of HIMS. Crewe Advisors LLC bought a new position in shares of Hims & Hers Health during the 4th quarter worth $28,000. Raleigh Capital Management Inc. increased its stake in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. raised its position in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after buying an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC bought a new position in Hims & Hers Health in the 4th quarter worth approximately $38,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on HIMS. Truist Financial dropped their price target on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research note on Thursday, April 10th. BTIG Research started coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They issued a "buy" rating and a $35.00 target price for the company. Morgan Stanley downgraded Hims & Hers Health from an "overweight" rating to an "equal weight" rating and upped their price target for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Piper Sandler lifted their price target on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a research report on Tuesday, February 25th. Finally, Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, Hims & Hers Health has a consensus rating of "Hold" and an average price target of $38.25.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.